Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Radiopharmaceuticals: From Design to Applications"
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 6076
Special Issue Editor
Interests: radiopharmaceutical chemistry; PET chemistry; technetium/rhenium chemistry; medicinal chemistry
Special Issue Information
Radiopharmaceuticals play a pivotal role in nuclear medicine, where they are widely used as diagnostic and therapeutic agents with their most important applications found in the understanding of neurodegenerative diseases, myocardial imaging, and the diagnosis and treatment of cancer.
In the era of personalized medicine, there is an ever-increasing need to develop efficacious strategies for the detection, molecular characterization, and therapy of disease while avoiding painful, inconvenient, expensive, or unnecessary methods and treatments. Undeniably, target-specific radiopharmaceuticals able to address a certain pathophysiological situation provide the means for real-time and pain-free visualization as well as molecular characterization and quantification of disease, which could in turn enable more effective and personalized therapy planning.
Therefore, there is an ever-increasing demand for the availability of diverse probes able to interrogate the in vivo biology of disease. In particular, for the potential impact of nuclear medicine in patient management and personalized medicine to be fully realized, there remains an urgent need to develop new radiopharmaceuticals for molecular targets of disease relevance that are not currently addressed while exhibiting optimal in vivo performance. Nevertheless, the development of the ‘’ideal’’ radiopharmaceutical is challenging since a plethora of issues need to be addressed such as selectivity and specificity for the molecular target in question, feasible chemistry for clinical applications, and optimal pharmacokinetic characteristics.
This Special Issue is dedicated to all efforts towards the development of target-specific radiopharmaceuticals aiming to address unmet clinical needs, as well as novel methodologies for the design and development of more effective radiopharmaceuticals with optimal in vivo performance.
Dr. Aristeidis Chiotellis
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- targeted radionuclide therapy
- nuclear medicine
- molecular targets
- in vitro and in vivo studies
- personalized medicine